Drug Profile
Etanercept biosimilar - Coherus Biosciences
Alternative Names: BAX 2200; CHS-0214Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Coherus Biosciences
- Developer Coherus BioSciences; Daiichi Sankyo Company
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 01 Jul 2020 the US Court of Appeals for the Federal Circuit upholds the validity of patents of Amgen, regarding therapeutic fusion protein in etanercept
- 01 Jul 2020 Discontinued - Phase-III for Plaque psoriasis in USA, Australia, Canada, Germany, Israel, Poland, South Africa, Spain, United Kingdom (SC)
- 01 Jul 2020 Discontinued - Phase-III for Rheumatoid arthritis (Treatment-experienced) in USA, Belarus, France, Germany, Hungary, Israel, Poland, Russia, South Africa, Spain, United Kingdom (SC)